

美時公告 7 月自結合併新台幣 11 億 1 千萬元*Lotus Reported Unaudited July Revenues of NT\$1,108 Million*

2021 年 8 月 10 日，台北

August 10th, 2021, Taipei

特殊學名藥廠美時化學製藥（以下簡稱“美時”，台灣證券交易所股票代碼：1795）公佈 2021 年 7 月自結合併營收達新台幣 1,107,853 仟元，累計今年前 7 個月自結合併營收新台幣 8,108,197 仟元，較去年同期成長逾 3 成。

Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795) today announced that its consolidated sales for July 2021 was NT\$1,107,853 thousand, driving the sales for the first seven months to NT\$8,108,197 thousand at over 30% growth YoY.

本月亞太區域市場表現亮眼，不僅較上月成長逾 17%、並較去年同期增加近 34%，為整併東南亞市場業務以來單月最佳；其中，韓國旗下之品牌減重用藥 Qsymia 及口服避孕藥 Mercilon 營收成長強勁，帶動相關科別領域產品組合表現。外銷業務部分則受到戒應用藥 Buprenorphine/Naloxone 舌下含片客戶存貨調整，以及外銷癌症用藥尚處上市初期、客戶拉貨時程較為波動等因素影響而較為平淡。

Asian Business outperformed this month by growing more than 17% over last month and almost 34% over the same period last year to hit a record high sales since its infusion of SEA operations. Brand products, including anti-obesity Qsymia and oral contraceptive Mercilon in Korea, made strong progress and led the growth momentum of overall portfolio. Export Business was softer mainly due to inventory adjustments in the US distribution channels of Buprenorphine/Naloxone film and fluctuated order patterns during initial phase of Global Oncology.

新聞聯繫人 Contact:

美時製藥 投資人關係處長 樂君儀 (02)2700 5908 investor@lotuspharm.com

Angela Luan, Investor Relations Director**關於美時：**

美時化學製藥股份有限公司（股票代碼：1795）成立於 1966 年，為一以台灣為基地供應全球市場之學名藥廠，高價值產品線涵蓋中樞神經系統、心血管疾病、癌症、女性保健、減肥等，並以錠劑、膠

囊及軟膠囊劑型為主；美時自 2014 年成為艾威群集團的一員，現專注於快速成長的抗癌市場，並矢志透過整合台灣與韓國首屈一指的研發平台與其製造優勢嘉惠病患、員工與股東。美時的行銷與業務通路包含直營的亞洲市場及艾威群集團橫跨全球超過 30 個國家的商業網絡，此外，美時亦積極與一線藥廠就產品線策略結盟，是少數能進軍所有市場的新興藥廠。

About Lotus

Founded in 1966, Lotus is a generic company headquartered in Taiwan with high-value generic products covering CNS, CVS, oncology, women health, and anti-obesity drugs in tablets & hard/softgel capsule for global markets. It became an Alvogen Company in 2014. The primary focus of Lotus is on addressing the fast-growing oncology market. By aligning the company's internal development and manufacturing capabilities, Lotus aims to benefit patients, its employees and shareholders alike. The company boasts a best in class R&D and manufacturing platform across Taiwan and Korea. Further, Lotus can reach nearly every global market with its high value pipeline through the company's direct markets, relationship with Alvogen's commercial units spanning over 30 countries, and through alliances with top-tier pharma companies.

聲明：

本文件及同時發佈之相關資訊內含有預測性敘述。除針對已發生事實，所有對美時製藥(以下簡稱本公司)未來經營業務、可能發生之事件及展望(包括但不限於預測、目標、估算和營運計劃)之敘述皆屬預測性敘述。預測性敘述會受不同因素及不確定性的影響，造成與實際情況有相當差異，這些因素包括但不限於價格波動、實際需求、匯率變動、市占率、市場競爭情況，法律、金融及法規架構的改變、國際經濟暨金融市場情勢、政治風險、成本估計等，及其他本公司控制範圍以外的風險與變數。這些預測性敘述是基於現況的預測和評估，本公司不負日後更新之責。